Immunophenotyping of Circulating Myeloid-Derived Suppressor Cells (MDSC) in the Peripheral Blood of Cancer Patients

Bruderek, Kirsten; Schirrmann, R; Brandau, Sven

doi:10.1007/978-1-0716-1060-2_1

Cited by 7 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No patient had received chemotherapy during the year before the collection of blood or tumor samples, nor had they taken corticosteroids, except for patient A017 in Fig 2 . NDN and mononuclear cells were isolated from blood for flow cytometric analysis or sorting following the published strategy ( Bronte et al, 2016 ; Bruderek et al, 2021 ) ( Fig 1A and B ). We rarely obtained enough TAN for further experimentation.…”

Section: Resultsmentioning

confidence: 99%

Immunosuppressive low-density neutrophils in the blood of cancer patients display a mature phenotype

Vanhaver,

Aboubakar Nana,

Delhez

et al. 2023

Life Sci. Alliance

View full text Add to dashboard Cite

The presence of human neutrophils in the tumor microenvironment is strongly correlated to poor overall survival. Most previous studies have focused on the immunosuppressive capacities of low-density neutrophils (LDN), also referred to as granulocytic myeloid-derived suppressor cells, which are elevated in number in the blood of many cancer patients. We observed two types of LDN in the blood of lung cancer and ovarian carcinoma patients: CD45highLDN, which suppressed T-cell proliferation and displayed mature morphology, and CD45lowLDN, which were immature and non-suppressive. We simultaneously evaluated the classical normal-density neutrophils (NDN) and, when available, tumor-associated neutrophils. We observed that NDN from cancer patients suppressed T-cell proliferation, and NDN from healthy donors did not, despite few transcriptomic differences. Hence, the immunosuppression mediated by neutrophils in the blood of cancer patients is not dependent on the cells’ density but rather on their maturity.

show abstract

Section: Resultsmentioning

confidence: 99%

Immunosuppressive low-density neutrophils in the blood of cancer patients display a mature phenotype

Vanhaver,

Aboubakar Nana,

Delhez

et al. 2023

Life Sci. Alliance

View full text Add to dashboard Cite

show abstract

“…Early-stage MDSCs (e-MDSCs, HLA-DR − CD33 dim CD66b − cells) lacking macrophage and granulocyte markers have been shown to accumulate in several diseases [28,29], such as hepatitis B virus (HBV) infection and cardiovascular The plasticity and differentiation patterns of MDSCs are dependent on disease conditions or environment [27]. Early-stage MDSCs (e-MDSCs, HLA-DR − CD33 dim CD66b − cells) lacking macrophage and granulocyte markers have been shown to accumulate in several diseases [28,29], such as hepatitis B virus (HBV) infection and cardiovascular disease. In addition, single-cell RNA sequencing data indicate that specific subtypes of MDSCs are shown in liver diseases [30,31].…”

Section: The Classification and Markers Of Mdscs In Mouse And Human L...mentioning

confidence: 99%

The Roles of Myeloid-Derived Suppressor Cells in Liver Disease

Zhang,

Sui,

Liu

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Liver disease-related mortality is a major cause of death worldwide. Hepatic innate and adaptive immune cells play diverse roles in liver homeostasis and disease. Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells. MDSCs can be broadly divided into monocytic MDSCs and polymorphonuclear or granulocytic MDSCs, and they functionally interact with both liver parenchymal and nonparenchymal cells, such as hepatocytes and regulatory T cells, to impact liver disease progression. The infiltration and activation of MDSCs in liver disease can be regulated by inflammatory chemokines and cytokines, tumor-associated fibroblasts, epigenetic regulation factors, and gut microbiota during liver injury and cancer. Given the pivotal roles of MDSCs in advanced liver diseases, they can be targeted to treat primary and metastatic liver cancer, liver generation, alcoholic and nonalcoholic liver disease, and autoimmune hepatitis. Currently, several treatments such as the antioxidant and anti-inflammatory agent berberine are under preclinical and clinical investigation to evaluate their therapeutic efficacy on liver disease and their effect on MDSC infiltration and function. Phenotypic alteration of MDSCs in different liver diseases that are in a model-dependent manner and lack special markers for distinct MDSCs are challenges for targeting MDSCs to treat liver disease. Multi-omics study is an option to uncover the features of disease-specific MDSCs and potential gene or protein targets for liver disease treatment. In summary, MDSCs play important roles in the pathogenesis and progression of liver disease by regulating both intrahepatic innate and adaptive immune responses.

show abstract

“…Based on this work, they established a standard protocol for isolation, identification, and characterization of human MDSC 91 . Moreover, our group has provided a flow cytometry analysis strategy for immunophenotyping of MDSC 92 as well as assays to evaluate immunosuppressive functions of these cells over T cells, including dye dilution proliferation assay and detection of IFN‐γ production by T cells using sandwich ELISA 93 …”

Section: Mdsc Concept: Strength and Weaknessmentioning

confidence: 99%

N1 versus N2 and PMN‐MDSC: A critical appraisal of current concepts on tumor‐associated neutrophils and new directions for human oncology

Antuamwine

Bosnjakovic

Hofmann‐Vega

et al. 2022

Immunological Reviews

Self Cite

View full text Add to dashboard Cite

Summary Research on tumor‐associated neutrophils (TAN) currently surges because of the well‐documented strong clinical relevance of tumor‐infiltrating neutrophils. This relevance is illustrated by strong correlations between high frequencies of intratumoral neutrophils and poor outcome in the majority of human cancers. Recent high‐dimensional analysis of murine neutrophils provides evidence for unexpected plasticity of neutrophils in murine models of cancer and other inflammatory non‐malignant diseases. New analysis tools enable deeper insight into the process of neutrophil differentiation and maturation. These technological and scientific developments led to the description of an ever‐increasing number of distinct transcriptional states and associated phenotypes in murine models of disease and more recently also in humans. At present, functional validation of these different transcriptional states and potential phenotypes in cancer is lacking. Current functional concepts on neutrophils in cancer rely mainly on the myeloid‐derived suppressor cell (MDSC) concept and the dichotomous and simple N1–N2 paradigm. In this manuscript, we review the historic development of those concepts, critically evaluate these concepts against the background of our own work and provide suggestions for a refinement of current concepts in order to facilitate the transition of TAN research from experimental insight to clinical translation.

show abstract

Immunophenotyping of Circulating Myeloid-Derived Suppressor Cells (MDSC) in the Peripheral Blood of Cancer Patients

Cited by 7 publications

References 8 publications

Immunosuppressive low-density neutrophils in the blood of cancer patients display a mature phenotype

Immunosuppressive low-density neutrophils in the blood of cancer patients display a mature phenotype

The Roles of Myeloid-Derived Suppressor Cells in Liver Disease

N1 versus N2 and PMN‐MDSC: A critical appraisal of current concepts on tumor‐associated neutrophils and new directions for human oncology

Contact Info

Product

Resources

About